Tag Archives: Everolimus
FDA Approved Afinitor for a Type of Advanced Pancreatic Cancer
The US Food and Drug Administration (FDA) has approved everolimus (Afinitor) to treat patients with advanced pancreatic neuroendocrine tumors (pNETs). pNETs is a rare, slow-growing form of pancreatic cancer. In theUnited States, there are fewer than 1000 new pNET cases … Continue reading
FDA Approves the First Drug for Tuberous Sclerosis Tumors
Good news for patients with subependymal giant cell astrocytoma (SEGA). The US Food and Drug Administration (FDA) has granted the approval for everolimus (Afinitor, Novartis) as the first medication for children and adults with SEGA who require therapeutic intervention but … Continue reading
Everolimus (Affinitor) Improves Survival in Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors affect the hormone-producing tissues within the pancreas, and have an incidence rate, affecting only 2 to 4 people per million worldwide. The incidence, however, is rising, and has quadrupled in the past 30 years, according to data … Continue reading